Locations:
SearchHeart team approach essential for individual patient decisions
Recent results from the SURTAVI trial add to mounting evidence that transcatheter aortic valve replacement (TAVR) can fully match surgical aortic valve replacement for safety and efficacy in appropriately selected patients at intermediate surgical risk. In the one-minute video below, Cleveland Clinic interventional cardiologist Amar Krishnaswamy, MD, puts the SURTAVI findings in context and offers perspective on the heart team approach that’s needed to help patients make the best choice between these two good treatment options.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
For a more detailed (eight-minute) video by Dr. Krishnaswamy on TAVR’s role in intermediate-risk patients, see the video here.
Advertisement
Advertisement
How our first century has impacted cardiovascular practice
Review offers comprehensive assessment of the landscape for wearables and more
Preserving trust in research requires vigilance and consensus around statistical nuances
Cardiac surgeon Patrick Vargo, MD, reflects on his first year as Cleveland Clinic staff
Improved risk prediction for patients is at the heart of Dr. Aaron Weiss’ research interests
Centralization would likely bring better outcomes, experts say, but may not be feasible
Dr. Daniel Burns on mentorship, robotic valve surgery, statistics and more
JACC review makes the case and outlines how to ensure oversight